Literature DB >> 22801267

[Angiotensin(1-7) attenuates left ventricular dysfunction and myocardial apoptosis on rat model of adriamycin-induced dilated cardiomyopathy].

Hong-zhi Liu1, Chuan-yu Gao, Xian-qing Wang, Hai-xia Fu, Hong-hui Yang, Xian-pei Wang, Yu-hao Liu, Mu-wei Li, Zhen-min Niu, Guo-you Dai, Da-tun Qi, You Zhang.   

Abstract

OBJECTIVE: To investigate the effect of Angiotensin(1-7) [Ang(1-7)] on left ventricular dysfunction and myocardial apoptosis on rat model of adriamycin-induced dilated cardiomyopathy (ADR-DCM).
METHODS: Weight-matched adult male Wistar rats were randomly divided into 3 groups: (1) the ADR-DCM group (n = 25), in which 2.5 mg/kg of ADR was weekly intravenously injected for 10 weeks. (2) Ang(1-7) group (n = 25), in which ADR rats were simultaneously treated with angiotensin-(1-7) (24 µg×kg(-1)×h(-1), ip.) for 12 weeks. (3) normal control group (n = 10). Hemodynamics and echocardiography examination were performed at 12 weeks. The malondialdehyde (MDA) was measured by TBA methods. The plasma concentration of AngII was determined by immunoradiometric assay. The pathological change was analyzed by histological hematoxylin-eosin staining. Myocardial apoptosis was assessed by TUNEL method. The protein expression of pro-apoptotic protein caspase-3, Bax and anti-apoptotic protein Bcl-xl in cardiomyocytes were detected by Western blot.
RESULTS: Mortality was significantly lower in Ang(1-7) group than in ADR-DCM group (16% vs. 40%, P < 0.01). Compared to the control group, left ventricular end-diastolic diameter (LVEDD), left ventricular end systolic diameter (LVESD) and left ventricular end-diastolic pressure (LVEDP) were significantly increased in ADR-DCM group (all P < 0.01) while fractional shorting (FS), +dp/dtmax and -dp/dtmax were significantly reduced in ADR-DCM group (all P < 0.01). LVEDD, LVESD and LVEDP were significantly reduced while FS, +dp/dtmax and -dp/dtmax were significantly higher in Ang(1-7) group compared to the ADR-DCM group, but still higher than the control group (all P < 0.01). The concentrations of AngII and MDA were higher in the ADR-DCM group than in the control group (P < 0.01), which were significantly reduced by Ang(1-7) treatment (P < 0.01). The TUNEL-positive cells and apoptosis index, the expression of pro-apoptotic protein caspase-3 and Bax were significantly higher while the expression of anti-apoptotic protein Bcl-xl was significantly lower in the ADR-DCM group than in the control group (all P < 0.01) which could all be partially reversed by Ang(1-7) treatment (all P < 0.01).
CONCLUSION: Ang(1-7) could significantly attenuate left ventricular dysfunction and myocardial apoptosis in this model by downregulating pro-apoptotic protein caspase-3 and Bax and upregulating anti-apoptotic protein Bcl-xl expression.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22801267

Source DB:  PubMed          Journal:  Zhonghua Xin Xue Guan Bing Za Zhi        ISSN: 0253-3758


  4 in total

1.  Developing a rat model of dilated cardiomyopathy with improved survival.

Authors:  Li-Juan Shen; Shu Lu; Yong-Hua Zhou; Lan Li; Qing-Min Xing; Yong-Liang Xu
Journal:  J Zhejiang Univ Sci B       Date:  2016 Dec.       Impact factor: 3.066

Review 2.  The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7).

Authors:  Robson Augusto Souza Santos; Walkyria Oliveira Sampaio; Andreia C Alzamora; Daisy Motta-Santos; Natalia Alenina; Michael Bader; Maria Jose Campagnole-Santos
Journal:  Physiol Rev       Date:  2018-01-01       Impact factor: 37.312

3.  Alamandine alleviated heart failure and fibrosis in myocardial infarction mice.

Authors:  Kun Zhao; Tianhua Xu; Yukang Mao; Xiaoguang Wu; Dongxu Hua; Yanhui Sheng; Peng Li
Journal:  Biol Direct       Date:  2022-09-27       Impact factor: 7.173

Review 4.  Anthracycline-induced cardiotoxicity and renin-angiotensin-aldosterone system-from molecular mechanisms to therapeutic applications.

Authors:  Paweł Sobczuk; Magdalena Czerwińska; Marcin Kleibert; Agnieszka Cudnoch-Jędrzejewska
Journal:  Heart Fail Rev       Date:  2022-01       Impact factor: 4.214

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.